Skip to content

Alopexx (ALPX) IPO deck

Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG).

This post is for subscribers only


Already have an account? Sign In